Dorzolamide: Development and clinical application of a topical carbonic anhydrase inhibitor

Survey of Ophthalmology

Volumn 42, Issue 2, 1997, Pages 137-151

  Pfeiffer, Norbert ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Carbonic anhydrase inhibitor; Dorzolamide; Glaucoma; Intraocular pressure; Medical treatment

Indexed keywords

DORZOLAMIDE;

ALLERGIC REACTION; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, TOPICAL; ANIMALS; CARBONIC ANHYDRASE INHIBITORS; DRUG EVALUATION; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OPHTHALMIC SOLUTIONS; SAFETY; SULFONAMIDES; THIOPHENES; TREATMENT OUTCOME;

EID: 0030808702     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(97)00053-2     Document Type: Review

References (203)

1. Abeshouse BS, Applefeld W: Citrate metabolism in urolithiasis. Sinai Hosp J 5:73-85, 1956
2. Anderson CJ, Kaufman PL, Sturm R: Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin. Am J Ophthalmol 86:516-519, 1978
3. Andreani D, Lepri G: Observations on transitory myopia from treatment with acetazolamide. Ann Ottalmol Clin Ocul 87:713-720, 1961
4. Arentsen IS: A case of acute myopia with glaucoma from ingestion of Diamox. Arch Chilenos Oftalmol 13:82-84, 1956
5. Arora YC: Agranulocytosis following acetazolamide therapy. New York State Med J 59:1119-1120, 1959
6. Ayvazian JH, Ayvazian LF: A study of the hyperuricemia induced by hydro-chlorothiazide and acetazolamide separately and in combination. J Clin Invest 40:1961-1966, 1961
7. Back M: Transient myopia after use of acetazolamide. Arch Ophthalmol 55:546-547, 1956
8. Baldwin J, Ponticello G, Anderson P, et al: Thienothiopyran-2-sulfonamides: Novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J Med Chem 32:2510-2513, 1989
9. Bar-Ilan A: The effects of separate and combined topical treatment with timolol maleate and trifluormethazolamide on the intraocular pressure in normal rabbits. Curr Eye Res 3:1305-1312, 1984
10. Bar-Ilan A, Pessah NI, Maren TH: Ocular penetration and hypotensive activity of the topically applied carbonic anhydrase inhibitor L-645,151. J Ocular Pharmacol 2:109-120, 1986
11. Barraquer J, Escribano J: Renal colic in the course of treatment with acetazolamide. Rev Clin Esp 64:310-313, 1957
12. Becker B: Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox. Am J Ophthalmol 37:13-15, 1954
13. Becker B: The mechanism of the fall in intraocular pressure induced by the carbonic anhydrase inhibitor, Diamox. Am J Ophthalmol 39:177-184, 1954
14. Benedict O, Zirm M, Harnoncourt K: Die Beziehungen zwischen metabolischer Azidose und intraokularem Druck nach Carboanhydrasehemmung mit Acetazolamid. Graefes Arch Clin Exp Ophthalmol 190:247-255, 1974
15. Bertino JR, Rodman T, Myerson RM: Thrombocytopenia and renal lesions associated with acetazolamide therapy. Arch Int Med 99:1006-1008, 1957
16. Biddle FG: Teratogenesis of acetazolamide in the CBA/J and SWV strains of mice. Teratology 11:31-46, 1965
17. Bietti GB, Virno M, Pecori-Giraldi J, Pellegrino N: Acetazolamide, metabolic acidosis and intraocular pressure. Am J Ophthalmol 80:360-369, 1975
18. Bietti GB, Virno M, Pecori-Giraldi J, Pivetti-Pezzi P: Blut-Azidose und Augeninnendruck. Klin Monatsbl Augenheilkd 160:7-12, 1972
19. Block ER, Rostand RA: Carbonic anhydrase inhibition in glaucoma: hazard or benefit for the chronic lunger? Surv Ophthalmol 23:169-172, 1978
20. Borhani H, Rahimy MH, Peyman GA: Vitreoretinal toxicity of acetazolamide following intravitreal administration in the rabbit eye. Ophthalmic Surg 25:166-169, 1994
21. Boureau M: Acute myopia induced by acetazolamide. Ann Oculist 194:627-630, 1961
22. Bourgeois H, Bron A, Lippa E, et al: 2% L-671-152: Multipledose activity BID (abstract). Invest Ophth Vis Sci 30 (Suppl): 233, 1990
23. Bovino JA, Marcus DF: The mechanism of transient myopia induced by sulfonamide therapy. Am J Ophthalmol 94:99-104, 1982
24. Brechue WF, Maren TH: A comparison between the effect of topical and systemic carbonic anhydrase inhibitors of aqueous humor secretion. Exp Eye Res 57:67-78, 1993
25. Brechue WF, Maren TH: Carbonic anhydrase inhibitory activity and ocular pharmacology of organic sulfamates. J Pharmacol Exp Ther 264:670-675, 1993
26. Brechue WF, Maren TH: pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors. Invest Ophthalmol Vis Sci 34:2581-2587, 1993
27. Breinin GM, Görtz H: Carbonic anhydrase inhibitor acetazolamide (Diamox). Arch Ophthalmol 52:333-348, 1954
28. Buclin T, Biollaz J, Lippa EA, et al: Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects. Clin Pharmacol Ther 49:665-673, 1991
29. Camras DB: A triple-masked, primary therapy study of the efficacy and safety of BID and TID-dosed brinzolamide 1% compared to TID-dosed dorzolamide 2% and BID-dosed timolol 0.5%. Inv Ophthalmol Vis Sci 38 (Suppl):S560, 1997
30. Carmignani M, Scoppetta C, Ranelletti FO, Tonali P: Adverse interaction between acetazolamide and anticholinesterase drugs at the normal and myasthenic neuromuscular junction level. Int J Clin Pharmacol Ther Toxicol 22:140-144, 1984
31. Charron RC, Feldman F: Acetazolamide therapy with renal complications. Can J Ophthalmol 9:282-284, 1974
32. Chiang CH, Lee AR, Lin CH: Studies of topical carbonic anhydrase inhibitors: ocular hypotensive effect of thiadiazole derivatives. J Ocul Pharmacol 9:109-115, 1993
33. Christiansson J: Transient myopia after the administration of Diamox. Acta Ophthalmol 36:356-357, 1958
34. Connor J, Strahlman ER, Lippa EA, et al: A placebo-controlled clinical trial of 0.7% dorzolamide (MK-507) and timolol (abstract). Invest Ophthalmol Vis Sci 35 (Suppl): 2177, 1994
35. Connor J, Keilani R, Segal R, et al: Pharmacocinetics and safety of dorzolamide (MK-507) in patients with moderate renal impairment (abstract). Invest Ophthalmol Vis Sci 36 (Suppl):738, 1995
36. Conroy CW, Maren TH: Effect of pH on the ocular distribution of a topical carbonic anhydrase inhibitor. Exp Eye Res 61:213-222, 1995
37. Conroy CW, Wynns GC, Maren TM: Carbonic anhydrase inhibitors (CAI) do not reach the retina by the topical route (abstract). Invest Ophthalmol Vis Sci 35 (Suppl):2220, 1994
38. Cowan RA, Hartnell GG, Lowdell CP, et al: Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function. BMJ 289:347-348, 1984
39. Cox SN, Hay E, Bird AC: Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol 106:1190-1195, 1988
40. Critchlow AS, Freeborn SF, Roddie RA: Potassium supplements during treatment of glaucoma with acetazolamide. BMJ 289:21-21, 1984
41. Cyrlin M, Wilkerson M, Lippa EY, et al: Four week safety study of the topical CAI MK-507 (abstract). Invest Ophth Vis Sci 32 (Suppl) :989, 1991
42. Davies DW: Acetazolamide therapy with renal complications. BMJ 1:214-215, 1959
43. De Santis L, Sallee V, Barnes G, et al: The effect of topically applied analogs of the carbonic anhydrase inhibitor, ethoxzolamide, on intraocular pressure in alert laser-induced ocular hypertensive cynomolgus monkeys (abstract). Invest Ophthalmol Vis Sci 27 (Suppl):179, 1986
44. Dean T, Chen HH, May J: AL 4414A and AL 4623A are new topically active carbonic anhydrase inhibitors which demonstrate a long lasting ocular hypotensive effect in the lasered cynomolgus monkey (abstract). Invest Ophth Vis Sci 32 (Suppl):931, 1993
45. Diestelhorst M, Bechetoille A, Lippa E, et al: Zur Stereospezifität der Augendrucksenkung eines lokal applizierbaren Karboanhydrasehemmers. Fortschr Ophthalmol 87:131-133, 1990
46. Englund GW: Fatal pancytopenia and acetazolamide therapy. J Am Med Assoc 210:2282-2282, 1969
47. Epstein DL, Grant WM: Carbonic anhydrase inhibitor side effects. Arch Ophthalmol 95:1378-1382, 1977
48. Fanous MM, Maren TH: Comparison of intraocular pressure (IOP) lowering by topical (MK-417) and systemic (methazolamide. MZ) carbonic anhydrase inhibitors (CAI) in the rabbit (abstract). Invest Ophthalmol Vis Sci 35 (Suppl):2177, 1994
49. Farber MD, Lam S, Tessler HH, et al: Reduction of macular edema by acetazolamide in patients with chronic iridocyclitis: a randomised prospective crossover study. Br J Ophthalmol 78:4-7, 1994
50. Ferry AP, Lichting M: Gouty arthritis as a complication of acetazolamide (Diamox) therapy for glaucoma. Can J Ophthalmol 4:145-147, 1969
51. Filatov V, Guyer DR, Kalghatgi K, et al: Penetration of topical carbonic anhydrase inhibitor, MK-927 into the retina and the retinal pigment epithelium of a rabbit (abstract). Invest Ophthalmol Vis Sci 34 (Suppl):1426, 1993
52. Fishman GA, Gilbert LD, Anderson RJ, et al: Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa. Ophthalmology 101:687-693, 1991
53. Fishman GA, Gilbert LD, Fiscella RG, Kimura AE, Jampol LM: Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol 107:1445-1452, 1989
54. Flammer J, Drance SM: Effect of acetazolamide on the differential threshold. Arch Ophthalmol 101:1378-1380, 1983
55. Forth W: Das Problem groβer Dosen in der Pharmakologie. Dt Ärztebl 87:1178-1180, 1990
56. Foss RH: Local applicalion of Diamox. Am J Ophthalmol 39:336-339, 1955
57. Fowler WM: Personal communication cited by: Hoffman FG, Zimmerman SL and Reese JD: Fatal agranulocytosis associated with acetazolamide. N Engl J Med 262:242-244, 1960
58. Frascarelli R, Lucidi E, Cozalli G: The influence of sulfonamide diuretics on the urinary excretion of uric acid and on the uric acid level. Minerva Med 51:1954-1961, 1960
59. Fraunfelder FT, Meyer S, Bagby GC: Letter to the editor. Am J Ophthalmol 100:746-716, 1985
60. Fraunfelder FT, Meyer S, Bagby GC: Letter to the editor. Am J Ophthalmol 101:129-129, 1986
61. Friedman Z, Krupin T, Becker B: Ocular and systemic effects of acetazolamide in nephrectomized rabbits (abstract). Invest Ophthalmol Vis Sci 23 (Suppl):209-213, 1982
62. Guckel FJ, Brix G, Schmiedek P, et al: Cerebrovascular reserve capacity in patients with occlusive cerebrovascular disease. Radiology 201:405-412, 1996
63. Galin MA, Baras I, Zweifach P: Diamox-induced myopia. Am J Ophthalmol 54:237-240, 1962
64. Gamm E: Origination of side effects of acetazolamide. J Glaucoma 6:60-63, 1984
65. Gervasoni JP, Lippa EA, Biollaz J, et al: Absence of metabolic effects of a methyl-thienothiopyran-2-sulfonamide, a new carbonic anhydrase inhibitor (CAI) during a 2-week ocular administration. Clin Pharmacol Ther 49 (Suppl):192, 1991
66. Gill WB, Vermuelen CW: Causation of stones by two co-acting agents: Diamox and operative iusult on urinary tract. J Urol 88:103-109, 1962
67. Glushien AS, Fisher ER: Renal lesions of sulfonamide type after treatment with acetazolamide (Diamox). JAMA 160:204-206, 1956
68. Gohar MA, Tadros MA: Transient myopia after acetazolamide therapy. Bull Ophthalmol Soc Egypt 52:367-369, 1959
69. Goodfield M, Davis J, Jeffcoate W: Acetazolamide and symptomatic metabolic acidosis in mild renal failure. BMJ 284:422-422, 1982
70. Gordon EE, Sheeps SG: Effect of acetazolamide on citrate excretion and formation of renal calculi. N Engl J Med 256: 1215-1218, 1957
71. Gortz H: Zur transitorischen Myopie nach Diamox. Klin Monatsbl Augenheilkd 137:21-25, 1960
72. Grant WM, Trotter RR: Diamox (acetazolamide) in treatment of glaucoma. Arch Ophthalmol 51:735-739, 1954
73. Green H, Bocher CA, Leopold IH: Carbonic anhydrase and the elaboration of bicarbonate ion in the rabbit eye. Arch Ophthalmol 53:472-477, 1955
74. Green H, Capper SA, Bocher CA, Leopold IH: Effect of acetazolamide (Diamox) on carbonic anhydrase activity of anterior uvea of the rabbit eye. Arch Ophthalmol 52:758-702, 1954
75. Grove J, Quint M-P, Plazonnet B: Influence of pH on the ocular penetration of the topical carbonic anhydrase inhibitor, MK-507, in the albino rabbit. Invest Ophthal Vis Sci 36:159, 1995
76. Gunning F, Bechetoille A, Lippa EA, et al: Sezolamide additivity to timolol twice daily. Eye 6:525-529, 1992
77. Gunning FP, Greve EL, Bron AM, et al: Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: a multiple-dose efficacy study. Graefes Arch Clin Exp Ophthalmol 231:384-388, 1993
78. Halpern AE, Kulvin MM: Transient myopia during treatment with carbonic anhydrase inhibitors. Am J Ophthalmol 48:534-535, 1959
79. Harris A, Arend O, Arend S, Martin B: Effects of topical dorzolamide on retinal and retrobulbar hemodynamics. Acta Ophthalmol Scand 74:569-572, 1996
80. Hasegawa T, Hara K, Hata S: Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro. Drug Metab Dispos 22;377-382, 1994
81. Heijl A, Strahlman E, Sverrisson T, Brinchman-Hansen O, Puustjarvi T, Tipping R: A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology 104:137-142, 1997
82. Heller I, Halevy J, Cohen S, Theodor E: Significant metabolic acidosis induced by acetazolamide: not a rare complication. Arch Intent Med 145:1815-1820, 1985
83. Higginbotham EJ, Kass MA, Lippa EA, et al: MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action. Arch Ophthalmol 108:65-68, 1990
84. Hill JB: Salicylate intoxication. N Engl J Med 288:1110-1113, 1973
85. Hoffman FG, Zimmerman SL, Reese JD: Fatal agranulocytosis associated with acetazolamide. N Engl J Med 262:242-244, 1960
86. Hofmann HM, Feicht B, Brunner-Ferber E, Lippa E, von Denffer H: MK-507 (L-671 152): lokale Verträglichkeit und Wirksamkeit eines neuen lokalen Karboanhydrasehemmers bei gesunden Probanden. Fortschr Ophthalmol 88:513-514, 1991
87. Holthöfer H, Siegel GJ, Tarkkanen A, Tervo T: Immunocytochemical localization of carbonic anhydrase, NaK-ATPase and the bicarbonate chloride exchanger in the anterior segment of the human eye. Acta Ophthalmol 69:149-154, 1991
88. Hunt CA, Mallorga PJ, Michelson SR, et al: 3-substituted thieno[2,3-b][1,4]thiazine-6-sulfonamides. A novel class of topically active carbonic anhydrase inhibitors. J Med Chem 37:240-247, 1994
89. Hutzelmann J, Snyder E, Tipping R, Adamsons I: Comparison of the IOP lowering effect of 2.0% dorzolamide TID in patients with light and dark irides (abstract). Invest Ophthalmol Vis Sci 37 (Suppl):5062, 1996
90. Jampel HD, Zack DJ: Expression of carbonic anhydrase isozymes in the ciliary epithelium and other tissues of the rabbit eye (abstract). Invest Ophthalmol Vis Sci 35 (Suppl): 1732, 1994
91. Johnson T, Kass MA: Letter to the editor. Am J Ophthalmol '101:128-129, 1986
92. Kalina PH, Shetlar DJ, Lewis RA, et al: 6-Amino-2-benzothiazolesulfonamide. The effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal eye. Ophthalmology 95:772-777, 1988
93. Kass MA, Kolker AE, Gordon M, et al: Acetazolamide and urolithiasis. Ophthalmology 88:261-265, 1981
94. Kass MA, Laibovitz RA, Lippa EA, et al: Comparative activity of 3% MK-507, a topical CAI with betaxolol (abstract). Invest Ophthalmol Vis Sci 32 (Suppl):989, 1991
95. Katz IM, Berger ET: Effect of iris pigmentation on response of ocular pressure to timolol. Surv Ophthalmol 23:395-398, 1979
96. Kitazawa Y, Azuma I, Araie M, Shirato S: Topical dorzolamide hydrochloride can be a substitute for oral carbonic anhydrase inhibitors (abstract). Invest Ophthalmol Vis Sci 35 (Suppl):2177, 1994
97. Kondo T, Matsuo M, Takahashi Y: Urolithiasis during treatment of carbonic anhydrase inhibitors. Folia Ophthalmol Jpn 19:576-584, 1968
98. Konowal A, Epstein RJ, Dennis RF, Brown SVI: Irreversible corneal decompensation in patients treated with topical dorzolamide (abstract). Invest Ophthalmol Vis Sci 37 (Suppl):376, 1996
99. Kronning E: Transient myopia following the use of acetazolamide. Acta Ophthalmol 35:478-484, 1957
100. Krupin T, Sly WS, Whyte MP, Dodgson SJ: Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency. Am J Ophthalmol 99:396-399, 1985
101. Kuang K, Xu M, Koniarek J, Fischbarg J: Effects of ambient bicarbonate, phosphate and carbonic anhydrase inhibitors on fluid transport across rabbit corneal endothelium. Exp Eye Res 50:187-493, 1990
102. Laibovitz R, Strahlrnan ER, Barber BL, Strohmaier KM: Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma. J Glaucoma 4:306-313, 1995
103. Layton WM Jr: Teratogenic action of acetazolamide in golden hamsters. Teratology 4:95-101, 1971
104. Layton WM Jr, Hallesy DW: Deformity of forelimb in rats: Association with high doses of acetazolamide. Science 149:306-308, 1965
105. Lee VHI., Robinson JR: Disposition of pilocarpine in the pigmented rabbit eye. Int J Pharm 11:155-165, 1982
106. Lehmann G, Linner G, Wistrand PJ: The pharmacokinetics of acetazolamide in relation to its use in the treatment of glaucoma and its effect as an inhibitor of carbonic anhydrase, in Rospe G (ed): Schering Workshop in Pharmacokinetics, Advances in the Biosciences, Vol 5. New York, Pergamon Press, 1969
107. Lesure P, Feicht B, Lippa EA, et al: Enhancement of BID activity of a topical CAI by formulation in Gelrite solution (abstract). Invest Ophthalmol Vis Sci 32 (Suppl):1293, 1991
108. Lewis RA, Schoenwald RD, Barfknecht CF, Phelps CD: Aminozolamide Gel, a trial of a topical carbonic anhydrase inhibitor in ocular hypertension. Arch Ophthalmol 104:842-844, 1986
109. Lewis RA, Schoenwald RD, Eller MG, et al: Ethoxzolamide analogue gel. Arch Ophthalmol 102:1821-1824, 1984
110. Lichter PR: Carbonic anhydrase inhibitors, blood dyscrasias, and standard-of-care. Ophthalmol 95:711-712, 1988
111. Lin JH, Chen IW, Lin TH: Species-dependent stereopharmacokinetics of MK-927, a potent carbonic anhydrase inhibitor. Drug Melab Dispos Bio Fate Chem 19:816-822, 1991
112. Lin JH, Lin TH, Cheng H: Uptake and stereoselective binding of the enantiomers of MK-927, a potent carbonic anhydrase inhibitor, by human erythocytes in vitro. Pharm Res 9:339-311, 1992
113. Lippa EA, Carlson LE, Ehinger B, et al: Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 110:495-499, 1992
114. Lippa EA, Clineschmidt CM, Tipping RW, Strohmaier KM, Dorzolamide Dose-Response Study Group: Dorzolamide hydrochloride: Six-week, dose-response study of an active topical carbonic anhydrase inhibitor (abstract). Invest Ophthalmol Vis Sci 34 (Suppl):931, 1993
115. Lippa EA, Laibovitz R, Clineschmidt C: L-671,152: Local tolerability and activity of a new topical carbonic anhydrase inhibitor in patients. Presented at the international Glaucoma Symposium of the XXVI international congress of Ophthalmology, Singapore, March 17, 1990
116. Lippa EA, Schuman JS, Higginbotham EJ, et al: MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 98:308-312, 1991
117. Lubeck MJ: Aplastic anemia following acetazolamide therapy. Am J Ophthalmol 69:684-085, 1970
118. Lyons JS, Krohn DL: Pilocarpine uptake by pigmented uveal tissue. Am J Ophthalmol 75:883-885, 1974
119. MacKenzie AR: Acetazolamide-induced renal stone. J Urol 84:453-455, 1960
120. Macri FJ, Brown JG: The constrictive action of acetazolamide on the iris arteries of the cat. Arch Ophthalmol 66:570-577, 1961
121. Maisey DN, Brown RD: Acetazolamide and symptomatic metabolic acidosis in mild renal failure. BMJ 283:1527-1528, 1981
122. Mallette LE: Anticonvulsants, acetazolamide and osteomalacia. New Engl J Med 293,2:668-668, 1975
123. Manners RM, Alexander MM, Martin DB, Elkington A: A study of topical carbonic anhydrase inhibitors in ocular hypertensive patients. Glaucoma 15:51-54, 1993
124. Maren TH: Teratology and carbonic anhydrase inhibition. Arch Ophthalmol 85:1-2, 1971
125. Maren TH: The development of ideas concerning the role of carbonic anhydrase in the secretion of aqueous humor: relation to the treatment of glaucoma, in Drance SM, Neufeld AH (eds): Glaucoma: Applied Pharmacology in Medical Treatment. Orlando, Grune & Stratton, 1984
126. Maren TH: Carbonic anhydrase: General perspectives and advances in glaucoma research. Drug Dev Res 10:255-276, 1987
127. Maren TH: The links among biochemistry, physiology and pharmacology in carbonic anhydrase mediated systems, in Botre F, Gros G, Storey BT (eds): Carbonic Anhydrase. New York, Basel, Cambridge, Weinheim, pp 186-207, 1991
128. Maren TH: The development of topical carbonic anhydrase inhibitors. J Glaucoma 4:49-62, 1995
129. Maren TH, Bar-Ilan A, Conroy CW, Brechue WF: Chemical and pharmacological properties of MK-927, a sulfonamide carbonic anhydrase inhibitor that lowers intraocular pressure by the topical route. Exp Eye Res 50:27-36, 1990
130. Maren TH, Bar-Ilan A: Effect of 6-OH benzo[b]thiopene-2-sulfonamide, a new topical carbonic anhydrase (CA) inhibitor on intraocular pressure in rabbits (abstract). Invest Ophthalmol Vis Sci 28 (Suppl):268, 1987
131. Maren TH, Bar-Ilan A: Ocular pharmacology and hypotensive activity of a topically active carbonic anhydrase (CA) inhibitor, a 4-alkylaminothienothiopyran-2-sulfonamide, MK-927 (abstract). Invest Ophthalmol Vis Sci 29 (Suppl):16, 1988
132. Maren TH, Jankowska L, Sanyal G, Edelhauser HF: The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Exp Eye Res 36:457-480, 1983
133. Margo CE: Acetazolamide and advanced liver disease. Am J Ophthalmol 101:611-612, 1986
134. Matsuda I, Takekoshi Y, Shida N, et al: Renal tubular acidosis and skeletal demineralization in patients on long-term anticonvulsant therapy. J Pediatr 87:202-205, 1975
135. Matuszewski BK, Constanzer ML: Indirect chiral separation and analyses in human biological fluids of the stereoisomers of a thienothiopyran-2-sulfonamide (Trusopt), a novel carbonic anhydrase inhibitor with two chiral centers in the molecule. Chirality 4:515-519, 1992
136. Maus TL, Larsson LI, McLaren JW, Brubaker RF: Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol 115:45-49, 1997
137. McLaughlin MA, Holder L, Dean T, et al: Novel CAI isomers topically active for the reduction of IOP in rabbit and lasered monkey models (abstract). Invest Ophthalmol Vis Sci 34 (Suppl):930, 1993
138. McMahon CD, Laibovitz R: IOP lowering activity of the topical CAI MK-507 at 3% (abstract). Invest Ophth Vis Sci 32 (Suppl):1576, 1991
139. Melikian HE, Lieberman TW, Leopold IH: Ocular pigmentation and pressure and outflow response to pilocarpine and epinephrine. Am J Ophthalmol 72:70-73, 1971
140. Michelson SR, Schwam H, Baldwin JJ. et al: Topically instilled MK-927: Lack of correlation between corneal penetration rate constant and ocular hypotensive activity in rabbits (abstract). Invest Ophthalmol Vis Sci 30 (Suppl):24, 1989
141. Miller RD: Letter to the editor. Am J Ophthalmol 100:745-746, 1985
142. Mogk LG, Cyrlin MN: Blood dyscrasias and carbonic anhydrase inhibitors. Ophthalmology 95:708-771, 1988
143. Muirhead JF, Scheie HG: Transient myopia after acetazolamide. Arch Ophthalmol 63:315-318, 1960
144. Nagasubramanian S, Bloom J, Poinoosawmy D, Hitchings RA: The effects of a topical acetazolamide preparation on intraocular pressure in patients with ocular hypertension, in Krieglstein GK (ed): Glaucoma Update, III. Heidelberg, Springer, 1986, pp 255-259
145. Nardin G, Lewis R, Lippa EA, et al: Activity of the topical CAI MK-507 BID when added to timolol BID (abstract). Invest Ophthalmol Vis Sci 32 (Suppl):989, 1991
146. Nielson CB: The effect of carbonic anhydrase inhibition on central corneal thickness after cataract extraction. Acta Ophthalmol 58:985-990, 1980
147. Parfitt AM: Acetazolamide and sodium bicarbonate induced nephrocalcinosis and nephrolithiasis. Arch Intern Med 124: 736-740, 1969
148. Patil PN, Jacobowitz D: Unequal accumulation of adrenergic drugs by pigmented and nonpigmented iris. Am J Ophthalmol 78:470-477, 1974
149. Pearson JR: Agranulocylosis following Diamox therapy. JAMA 157:339-341, 1955
150. Pepys MB: Acetazolamide and renal stone formation. Lancet 1:837-837, 1970
151. Persky L, Chambers D, Potts A: Calculus formation and ureteral colic following acetazolamide (Diamox) therapy. JAMA 161:1625-1626, 1956
152. Pfeifler N: Entwicklung lokaler Karboanhydrasehemmer. Folia Ophthalmol 16:115-121, 1991
153. Pfeiffer N, Gerling J, Lippa EA, et al: Comparative tolerability of topical carbonic anhydrase inhibitor MK-927 and its S-enantiomer MK-417. Graefes Arch Clin Exp Ophthalmol 229:111-114, 1991
154. Pfeiffer N, Grehn F, Hennekes R, Garus H: Augeninnendrucksenkung nach Applikation des lokalen Karboanhydrasehemmers (MK-297)-Wirktungsvelgleich mit Pilocarpin. Fortschr Ophthalmol 87:128-130, 1990
155. Pfeiffer N, Hennekes R, Lippa EA. et al: A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients. Br J Ophthalmol 74:105-408, 1990
156. Pfeiffer N, Sell E, Winkgen A, et al: Dorzolamide in acute angle-closure glaucoma (abstract). Invest Ophthalmol Vis Sci 37 (Suppl):5050, 1996
157. Pierce WM Jr, Sharir M, Waite KJ, et al: Topically active ocular carbonic anhydrase inhibitors: novel biscarbonylamidothiadiazole sulfonamides as ocular hypotensive agents. Proc Soc Exp Biol Med Jul 203 (Suppl):360-365, 1993
158. Ponticello GS, Freedman MB, Habecker CN: Thienothiopyran-2-sulfonamides: A novel class of water-soluble carbonic anhydrase inhibitors. J Med Chem 30:591-597, 1987
159. Putnam ML, Schoenwald RD, Duffel MW: Ocular disposition of aminozolamide in the rabbit eye. Invest Ophthalmol Vis Sci 28:1373-1382, 1987
160. Reisner EH Jr, Morgan MC: Thrombocytopenia following acetazolamide (Diamox) therapy. JAMA 160:206-207, 1956
161. Rentiers PK, Johnston AC, Bushard N: Severe aplastic anemia as a complication of acetazolamide therapy. Can J Ophthalmol 5:337-342, 1970
162. Rodriguez-Gonzales A: Renal lithiasis resulting from use of inhibitors of carbonic anhydrase in ophthalmology. Arch Soc Oftalmol Hisp Am 26:232-234, 1966
163. Rubenstein MA, Bucy JG: Acetazolamide-induced renal calculi. J Urol 114:610-612, 1975
164. Schoenwald R, Putnam M, Barfknecht C, et al: Ocular disposition of aminozolamide in the rabbit eye (abstract). Invest Ophthalmol Vis Sci 27 (Suppl):348, 1986
165. Schoenwald RD, Eller MG, Dixson JA, Barfknecht CF: Topical carbonic anhydrase inhibitors. J Med Chem 27:810-812, 1984
166. Schwam H, Michelson SR, Sondy JM, Smith RL: L-645,151 a topically effective ocular hypotensive carbonic anhydrase inhibitor: Part I, biochemistry and metabolism (abstract). Invest Ophthalmol 25 (Suppl):180, 1984
167. Sears ML, Matsui H, Murakami M, et al: Localization of carbonic anhydrase (CA) mediated aqueous secretion to basolateral membranes of non-pigmented epithelium of ciliary process (abstract). Invest Ophthalmol Vis Sci 35 (Suppl): 1454, 1994
168. Sell EI, Pfeiffer N: Dorzolamide - a topical carbonic anhydrase inhibitor in refractory glaucoma. G J Ophthalmol 4 (Suppl):149, 1995
169. Serle JB, Lustgarten JS, Lippa EA, et al: MK-927, a topical carbonic anhydrase inhibitor. Dose response and reproducibility. Arch Ophthalmol 108:838-841, 1990
170. Serle JB, Lustgarten JS, Lippa EA, et al: Six week safety study of 2% MK-927 administered twice daily to ocular hypertensive volunteers. J Ocul Pharmacol 8:1-9, 1992
171. Serle JB, Podos SM, Lippa EA, Klotzbuecher CM: Compassionate case usage of dorzolamide (MK-507) in 16 glaucoma patients (abstract). Invest Ophthalmol Vis Sci 35 (Suppl): 2177, 1994
172. Shah A, Constant MA, Becker B: Urinary excretion of citrate in humans following administration of acetazolamide (Diamox). Arch Ophthalmol 59:536-540, 1958
173. Sharir M, Pierce WM, Chen D, Zimmerman T: Pharmacokinetics, acid-base balance and intraocular pressure effects of ethyloxaloylazolamide - a novel topically active carbonic anhydrase inhibitor. Exp Eye Res 58:107-116, 1994
174. Stein A, Pinke R, Krupin T, et al: The effect of topically administered carbonic anhydrase inhibitors on aqueous humor dynamics in rabbits. Am J Ophthalmol 95:222-228, 1983
175. Steinmetz RL, Fitzke FW, Bird AC: Treatment of cystoid macular edema with acetazolamide in a patient with serpiginous choroidopathy. Retina 11:412-415, 1991
176. Strahlman ER, Deasy D, Panebianco D, Timolol/Dorzolamide Combination Study Group: A two-week pilot activity study of a fixed combination of timolol and dorzolamide hydrochloride (abstract). Invest Ophthalmol Vis Sci 34 (Suppl): 931, 1993
177. Strahlman ER, Tipping R, Vogel R, International Dorzolamide Study Group: A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol 113:1009-1016, 1995
178. Strahlman ER, Vogel R, Tipping R, Clineschmidt CM: The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 103:1283-1293, 1996
179. Sugrue MF: The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther 12:363-376, 1996
180. Sugrue MF, Funk HA, Lazarides E, et al: Evidence for a role of membrane bound carbonic anhydrase in intraocular pressure regulation in rabbits (abstract) : Invest Ophthalmol Vis Sci 35(Suppl):1400, 1994
181. Sugrue MF, Gautheron P, Mallorga P, et al: L-662,583 is a topically effective carbonic anhydrase inhibitor in experimental animals. Br J Pharmacol 99:59-64, 1990
182. Sugrue MF, Gautheron P, Schmitt C, et al: On the pharmacology of L-645,151: a topically effective ocular hypotensive carbonic anhydrase inhibitor. J Pharmacol Exp Therapeutics 232:534-540, 1985
183. Sugrue MF, Mallorga P, Schwam H, et al: A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr Eye Res 9:607-615, 1990
184. Sugrue MF, O'Neill-Davis L: The effect of cyclooxygenase inhibition on the ocular hypotensive action of topical carbonic anhydrase inhibitors in rabbits. J Ocul Pharmacol 7:201-211, 1991
185. Sugrue MF, Waheed A, Sly WS, et al: A study of the in vitro inhibition of human carbonic anhydrase inhibitor isoenzymes I, II and IV (abstract). Invest Ophthalmol Vis Sci 34 (Suppl):930, 1993
186. Underwood LC: Fatal bone marrow depression after treatment with acetazolamide (Diamox). JAMA 161;1477-1477, 1956
187. Vickers TH: Acetazolamide dysmelia in rats. Br J Exp Pathol 53:5-21, 1972
188. Virno M, Malagola R, Motolese ED, Pecori-Giraldi J: Bluthyperosmolarität durch Acetazolamid und Augeninnendrucksenkung, in Krieglstein GK, Levdecker W (Eds): Medikamentöse Glaukomtherapie. München, JF Bergmann Verlag, 1982
189. Wallace TR, Fraunfelder FT, Petursson GJ, Epstein DC: Decreased libido - a side effect of carbonic anhydrase inhibitors. Ann Ophthalmol 11:1563-1566, 1979
190. Wang RF, Serle JB, Podos SM, Sugrue MF: The ocular hypotensive effect of the topical carbonic anhydrase (CA) inhibitor MK-927 in glaucomatous monkeys (abstract). Invest Ophthalmol Vis Sci 29 (Suppl):16, 1988
191. Wang RF, Serle JB, Podos SM, Sugrue MF: MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol 109:1297-1299, 1991
192. Weinstein L: Antibiotics, in Goodman LS, Gilman A (eds): The Pharmacological Basis of Therapeutics. London, Toronto, The Macmillan Company, 1970
193. Weiss IS: Hirsutism after chronic administration of acetazolamide. Am J Ophthal 78:327-330, 1974
194. Werner EB, Gerber DS, Yolande JY: Effect of a topical carbonic anhydrase inhibitor, 6-OH benzo[b]thiopene-2-sulfonamide, on intraocular pressure in normotensive subjects. Can J Ophthalmol 22:316-319, 1987
195. Wilkerson M, Cyrlin M, Lippa EA, et al: Four week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 111:1343-1350, 1993
196. Wish N, Fischbein FI, Siegel R, et al: Aplastic anemia resulting from the use of carbonic anhydrase inhibitors. Am J Ophthalmol 75:130-132, 1973
197. 2 equilibria. Am J Ophthalmol 50:291-297, 1960
198. Wistrand PJ: Distribution and function of carbonic anhydrase (CA) isoenzymes in the human eye. Relevance for the design of topical CA inhibitors. Abstract at the Int Congress for Eye Res., Stresa Italy, 1992
199. Wolfensberger TJ, Mahieu I, Boulton M, et al: Ultrastructural localisation of membrane-bound carbonic anhydrase (CA IV) in cultured human adult and fetal RPE. Invest Ophthalmol Vis Sci 34 (Suppl):981, 1993
200. Yamazaki Y, Miyamoto S, Sawa M: Effect of MK-507 on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol 38:92-96, 1994
201. Yamazaki Y, Miyamoto S, Sawa M: Fffect of topical carbonic anhydrase inhibitor (MK-507) on intraocular pressure in normal human eyes. Nippon Ganka Gakkai Zasshi 98:293-297, 1994
202. Yates-Bell JG: Renal colic and anuria from acetazolamide. BMJ 2:1392-1393, 1958
203. Zimran A, Beutler E: Can the risk of acetazolamide-induced aplastic anemia be decreased by periodic monitoring of blood cell counts? Am J Ophthalmol 104:654-658, 1987